Oncology Business Management | Specialty

Looming Questions, Challenges Facing Physicians in Prostate Cancer

November 22nd 2016

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.

Biomarkers, Combo Regimens Key to Mitigating AR-Resistance in mCRPC

November 21st 2016

A number of clinical trials are seeking to identify beneficial therapeutic outcomes in patients with prostate cancer who are resistant to androgen receptor–targeted agents.

New Guidelines Establish Recommendations for HER2 Testing for GEA

November 21st 2016

An expert panel has issued a set of guidelines for patients with gastroesophageal adenocarcinoma, recommending that they be tested for HER2 status before initiation of targeted therapy.

FDA Issues Complete Response Letter for Apaziquone in Bladder Cancer

November 19th 2016

The FDA has issued a complete response letter to Spectrum Pharmaceuticals informing the company that its new drug application for apaziquone in bladder cancer would not be approved.

Biomarker Development Key to Optimizing Immunotherapy in Lung Cancer

November 17th 2016

The expression of PD-L1 has been at the forefront of biomarker development for PD-1/PD-L1 inhibitors, but there is much uncertainty surrounding its use and other biomarkers are needed.

Dr. Goldberg on PD-L1 as a Biomarker in Lung Cancer

November 17th 2016

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses the use of PD-L1 as a biomarker in treating patients with lung cancer.

Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC

November 16th 2016

Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.

Mobile Screening Draws a Crowd

November 8th 2016

One group of oncologists has found a way to generate more business while at the same time addressing the unwillingness of people to come for screening.

The OCM Is Both Good and Questionable

November 7th 2016

The OCM program is a good start on a path that is as rough as it gets in our healthcare system that needs reform, which can't come from legislation such as Obamacare.

Nimble, Larger Practices Can Thrive Under New Healthcare Delivery Models

November 7th 2016

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

Experts Say ICD-10 Codes Don't Go Far Enough

November 4th 2016

When CMS switched from ICD-9 to ICD-10 last year, the new diagnosis classification list allowed coders to translate additional elements of doctors’ language to billers’ language. However, some coders would like to see that vocabulary expand further, particularly in the area of comorbidities and complications.

FDA Submission Completed for Niraparib in Ovarian Cancer

November 2nd 2016

A new drug application to the FDA has been completed for niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

IDO Inhibitors for Melanoma

October 31st 2016

Emerging Immunotherapy Combinations for Melanoma

October 31st 2016

Looking to the Future of Melanoma

October 31st 2016

Sequencing Strategies for Recurrent/Refractory Melanoma

October 31st 2016

Treatment Beyond Melanoma Progression

October 31st 2016

Abscopal Effect and Pseudoprogression in Melanoma

October 31st 2016

Single vs Dual Checkpoint Inhibition in Melanoma

October 31st 2016

Questions About Sequencing in BRAF-Mutant Melanoma

October 31st 2016